[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![PrismMarketView Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1257318598386696195.png) PRISM MarketView [@PrismMarketView](/creator/twitter/PrismMarketView) on x 4678 followers
Created: 2025-07-17 15:33:10 UTC

Actuate Therapeutics (Nasdaq: $ACTU) is moving forward with a Phase X trial after early results showed complete responses in two pediatric Ewing sarcoma patients treated with elraglusib.

With no approved targeted therapies for this aggressive cancer, Actuate aims to fill a major treatment gap. .@ActuateT


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945869391561630058/c:line.svg)

**Related Topics**
[approved](/topic/approved)
[$actu](/topic/$actu)
[nasdaq](/topic/nasdaq)
[prism](/topic/prism)

[Post Link](https://x.com/PrismMarketView/status/1945869391561630058)